Literature DB >> 20043215

A survey of prognostic value of serum factors in multiple myeloma patients before treatment: macrophage-colony stimulating factor (M-CSF) is a powerful predictor of survival.

Maria Kowalska1, Janina Kaminska, Malgorzata Fuksiewicz, Beata Kotowicz, Magdalena Chechlinska, Agnieszka Druzd-Sitek, Jan Walewski.   

Abstract

Cytokines are involved in the pathogenesis of multiple myeloma (MM) and other cancers. The aim of this study was to evaluate a range of cytokines of diverse activity in patients with multiple myeloma for a possible prognostic value. Concentrations of the following cytokines and cytokine receptors were measured by ELISA in the sera of 64 untreated MM patients: IL-6, IL-8, IL-10, TNFα, sTNF R I and II, sIL-2Rα, IL-1ra, M-CSF, G-CSF, VEGF, and bFGF. Serum levels of sTNF RI, IL-6, and bFGF were elevated in over 50% of patients. There was an inverse relationship between sTNF RII, TNFα, IL-1ra, and albumin levels. There was no significant relationship between cytokines/cytokine receptors and other serum correlates of myeloma. In a univariate survival analysis, β2-microglobulin, LDH, sIL-2Rα, sTNF RI, and M-CSF were significant variables. In a multivariate analysis, only M-CSF and β2-microglobulin retained a significant influence on survival. Serum M-CSF may be considered another independent and clinically useful prognostic factor in multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20043215     DOI: 10.1007/s12032-009-9403-9

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  31 in total

1.  Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer.

Authors:  Lukas A Hefler; Robert Zeillinger; Christoph Grimm; Anil K Sood; Wen Fang Cheng; Angiolo Gadducci; Clemens B Tempfer; Alexander Reinthaller
Journal:  Gynecol Oncol       Date:  2006-06-05       Impact factor: 5.482

2.  Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma.

Authors:  Tsuyoshi Iwasaki; Teruaki Hamano; Atsushi Ogata; Naoaki Hashimoto; Masayasu Kitano; Eizo Kakishita
Journal:  Br J Haematol       Date:  2002-03       Impact factor: 6.998

3.  Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I--an independent prognostic factor.

Authors:  J Kaminska; M P Nowacki; M Kowalska; A Rysinska; M Chwalinski; M Fuksiewicz; W Michalski; M Chechlinska
Journal:  Tumour Biol       Date:  2005-07-06

4.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

5.  Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.

Authors:  Niels Frost Andersen; Therese Standal; Johan Lanng Nielsen; Lene Heickendorff; Magne Borset; Flemming Brandt Sørensen; Niels Abildgaard
Journal:  Br J Haematol       Date:  2005-01       Impact factor: 6.998

6.  Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.

Authors:  F Di Raimondo; M P Azzaro; G Palumbo; S Bagnato; G Giustolisi; P Floridia; G Sortino; R Giustolisi
Journal:  Haematologica       Date:  2000-08       Impact factor: 9.941

Review 7.  Tumor necrosis factor-alpha-induced apoptosis in T cells from aged humans: a role of TNFR-I and downstream signaling molecules.

Authors:  Sudhir Gupta
Journal:  Exp Gerontol       Date:  2002 Jan-Mar       Impact factor: 4.032

8.  Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group.

Authors:  T T Pelliniemi; K Irjala; K Mattila; K Pulkki; A Rajamäki; A Tienhaara; M Laakso; R Lahtinen
Journal:  Blood       Date:  1995-02-01       Impact factor: 22.113

9.  Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis.

Authors:  Haiming Chen; Richard A Campbell; Yunchao Chang; Mingjie Li; Cathy S Wang; Jennifer Li; Eric Sanchez; Michael Share; Jeffrey Steinberg; Ariana Berenson; Dror Shalitin; Zhaohui Zeng; Dorina Gui; Pablo Perez-Pinera; Ronald J Berenson; Jonathan Said; Benjamin Bonavida; Thomas F Deuel; James R Berenson
Journal:  Blood       Date:  2008-12-05       Impact factor: 22.113

10.  M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis.

Authors:  Yoshiaki Kubota; Keiyo Takubo; Takatsune Shimizu; Hiroaki Ohno; Kazuo Kishi; Masabumi Shibuya; Hideyuki Saya; Toshio Suda
Journal:  J Exp Med       Date:  2009-04-27       Impact factor: 14.307

View more
  4 in total

1.  Exploration of macrophage colony-stimulating factor as a new type of tumor marker.

Authors:  Ru Zhou; Yiming Zhou; Zongyou Chen
Journal:  Biomed Rep       Date:  2013-09-25

2.  The systemic cytokine environment is permanently altered in multiple myeloma.

Authors:  Mary M Zheng; Zhifang Zhang; Kyle Bemis; Andrew R Belch; Linda M Pilarski; John E Shively; Julia Kirshner
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

3.  Increased expression of colony stimulating factor-1 is a predictor of poor prognosis in patients with clear-cell renal cell carcinoma.

Authors:  Liu Yang; Qian Wu; Le Xu; Weijuan Zhang; Yu Zhu; Haiou Liu; Jiejie Xu; Jianxin Gu
Journal:  BMC Cancer       Date:  2015-02-18       Impact factor: 4.430

Review 4.  Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma.

Authors:  Sabah Akhtar; Tayyiba A Ali; Ammara Faiyaz; Omar S Khan; Syed Shadab Raza; Michal Kulinski; Halima El Omri; Ajaz A Bhat; Shahab Uddin
Journal:  Int J Mol Sci       Date:  2020-07-15       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.